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Abstract 
 
Purpose: To assess the prevalence of Obstructive Sleep Apnoea (OSA) in a population 
with Macular Telangiectasia Type 2 (MacTel Type 2) and how OSA affects MacTel 
Type 2 progression. 
Methods: In this case-control study participants completed a questionnaire which 
incorporated the Berlin Questionnaire (BQ) and questions regarding anthropometric 
data and medical history. A subset was sequentially selected to undertake overnight 
sleep analysis using the ResMed ApneaLink™. Using data acquired from the 
Busselton Population and Medical Research Foundation participants were case-
matched based on age, sex and body mass index (BMI) along with, where possible, 
the presence of hypertension and diabetes.   
Results: There were 57 (30 ApneaLink™) MacTel Type 2 and 183 controls, 
respectively. There was no difference in self-reported sleep disordered breathing 
outcomes between the cohorts using the BQ (p=0.95).  Analysis of key indices from 
ApneaLink™ recordings found that those with an Apnoea -Hypopnoea Index (AHI) 
and Oxygen Desaturation Index (ODI) > 5 episodes per hour had a more advanced 
stage of MacTel Type 2 (AHI p = 0.05, ODI p = 0.03). An analysis of the 2 year MacTel 
Type 2 disease progression rates showed that those diagnosed with OSA progressed 
at the same rate as those without OSA. 
Conclusion: Patients with MacTel Type 2 have a high prevalence of OSA which 
appears to result in a more advanced form of the disease.   
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Glossary of Terms: 
AASM American Academy of Sleep Medicine  
AHI Apnoea-Hypopnoea Index  
anti-VEGF Anti-Vascular Endothelial Growth Factor  
BCVA Best Corrected Visual Acuity  
BMI Body Mass Index (kg/m2)  
BQ Berlin Questionnaire  
CI Confidence Interval  
CMT Central Macular Thickness (microns)  
CPAP Continuous Positive Airway Pressure  
CSCR Central Serous Chorioretinopathy   
DMO Diabetic Macula Oedema  
ESS Epworth Sleepiness Scale  
ETDRS Early Treatment Diabetic Retinopathy Study  
FA Fluorescein Angiography  
FAF Fundus Autofluorescence  
HI Hypopnoea Index  
HR-QoL Health Related Quality of Life  
hrs Hours  
Hz  Hertz  
IH  Intermittent Hypoxia  
INL Inner Nuclear Layer  
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IS Inner Segment  
IS/OS Inner Segment/Outer Segment  
IVTA Intravitreal Triamcinolone Acetate  
kg  Kilogram  
LogMAR Logarithm of Minimum Angle of Resolution  
MacTel Type 2 Idiopathic Macular Telangiectasia Type 2  
Mb Megabytes  
NEI-VFQ-25 National Eye Institute Visual Functioning Questionnaire  
NHOR Natural History and Observational Registry  
nm  Nanometres  
OCT Optical Coherence Tomography  
ODI Oxygen Desaturation Index   
OS Outer Segment  
OSA Obstructive Sleep Apnoea  
PDT Photodynamic Therapy  
P-value Probability Value  
RPE Retinal Pigment Epithelium   
SpO2 Saturation of Peripheral Oxygen  
VA Visual Acuity  
VEGF Vascular Endothelial Growth Factor  
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1.1 Idiopathic Macular Telangiectasia – MacTel Type 2: 
 
 
1.1.1  Background: 
 
Idiopathic macular telangiectasia is a slowly progressive disease of the macula, 
characterised clinically by dilatation, tortuosity and leak of the juxtafoveal capillaries, 
that was first described in 19822. Gass and Blodi provided a classification of the disease 
based on biomicroscopic and fluorescein angiographic examination in 19931. Within 
their classification they divided macular telangiectasia into types 1, 2 and 31-3. 
 
Type 1 Macular Telangiectasia is predominately unilateral with an increased 
prevalence in males1. Clinical features include visible telangiectatic vessels coupled 
with oedema and intraretinal lipid exudates in only one eye, which are seen as 
multiple capillary aneurysms with fluorescein angiography 1 3 4. 
 
Perifoveal, or type 2, macular telangiectasia generally presents in the fifth to seventh 
decades of life. It is characterised by loss of retinal transparency, superficial retinal 
crystalline deposits, foveal thinning and blunted or right-angled venuoles in both 
eyes, most apparent in the temporal parafoveal region of the macula1 4 5.Gass and 
Blodi also described 5 stages of Macular Telangiectasia type 2, helpful in monitoring 
progression of the condition1 (Table 1).  
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Disease Stage Appearance 
Stage 1 Mild, perifoveal, late stage hyperfluorescence on  angiography 
Stage 2 Loss of parafoveal retinal transparency 
Stage 3 Appearance of slightly dilated, blunted and right angled vessels 
Stage 4 Intraretinal pigment clumping 
Stage 5 Subretinal neovascularisation 
 
Gass and Blodi originally reported that MacTel Type 2 has an equal prevalence 
amongst males and females1. However, the baseline findings from an ongoing, global, 
multicentre observational study into the natural history and progression of MacTel 
Type 2, reported by Clemens et al., noted an increased proportion in females (64%, n 
= 198)5. 
 
The third and rarest form of macular telangiectasia is occlusive telangiectasia which 
on biomicroscopy shows visible telangiectatic vessels coupled with parafoveal 
vascular occlusion with minimal exudates1. Due to the rarity of type three macular 
telangiectasia, Yanuzzi4 subsequently redefined the classification of macular 
telangiectasia to two forms, Types 1 and 2, excluding type 3, which is now the 
preferred classification of the disease. 
 
Table 1: Gass and Blodi’s 1993 classification of Idiopathic Macular Telangiectasia Type 2 
1 
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This study is concerned exclusively with macular telangiectasia type 2 (MacTel Type 
2) since it is by far the commonest form of macular telangiectasia and it appears to 
develop through unique pathogenic mechanisms. 
 
1.1.2  Epidemiology: 
 
MacTel Type 2, formerly regarded as a rare condition5-9, appears to be more common 
than previously thought. Two population based studies aiming to establish the 
prevalence of MacTel Type 2 reported varying results. The Melbourne Collaborative 
Cohort Study examined fundus images of 22,062 subjects and found signs consistent 
with MacTel Type 2 in 5 subjects. This represented a prevalence estimate of 0.004% to 
0.023% or 5 - 23 cases per 100,000 adults over the age of 4710. By contrast, the Beaver 
Dam Eye Study reported a higher prevalence estimate of 0.1% (95% CI 0.09, 0.1) in 
their population-based sample of 4790 participants (43-86 years of age)7. The higher 
estimate of prevalence may be due to differences in methodology, with the Beaver 
Dam study grading stereoscopic colour photographs taken through dilated pupils, 
which are likely to have provided better quality images compared with the non-
stereoscopic photographs taken through undilated pupils that were used for grading 
by the Melbourne study. The prevalence of MacTel Type 2 in both the Melbourne 
Collaborative Cohort Study and the Beaver Dam Study was based solely on fundus 
photography in which only relatively advanced disease is apparent.  The authors of 
both studies noted that the use of either optical coherence tomography (OCT) or 
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fluorescein angiography (FA) would very likely have resulted in higher estimates of 
prevalence rates as these diagnostic tools are able to diagnose the disease in its earlier 
stages7 10. 
 
There is evidence to suggest that a cause of MacTel Type 2 may develop from a genetic 
abnormality. Through a prospective cross-sectional case series asymptomatic signs 
consistent with MacTel Type 2 were found in 5 relatives of 4 symptomatic patients, 
including 2 sets of monozygotic twins11. This is not a standalone case-series with the 
literature reporting other cases of familial manifestations of MacTel Type 212-14 
including several in monozygotic twins15-17. Why the manifestations become 
symptomatic in some family members and not in others is not understood, however, 
it has been postulated that potential environmental factors, genetic or combination of 
both may be a reason11. Gillies et al. also postulated that changes to the vascular 
network may be the “second hit” required to induce symptomatic changes. This 
would also help explain the higher prevalence of hypertension, diabetes and 
cardiovascular disease seen in patients with MacTel Type 25. 
 
 
1.1.3  Clinical Features: 
 
Detailed funduscopic examination using high powered magnification is mandatory in 
those with suspected macular telangiectasia. MacTel Type 2 is characteristically 
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bilateral in its nature, however the progression of the disease can vary between eyes5. 
Therefore, cases reported to be unilateral may represent an asymmetric disease 
progression with the apparently unaffected eye having only subtle early changes.  The 
temporal foveal region is the common location for early signs of the disease. The 
affected region in more advanced cases is generally in an area approximately one disc 
diameter in size with a horizontal oval appearance. 
 
The disease classification first proposed by Gass and Blodi in 1993 suggests that there 
is a chronological sequence of funduscopic and ophthalmological findings in MacTel 
Type 2. It is important to note that the clinical findings and frequency estimates 
reported in the literature may vary from true the prevalence due to varying stages of 
disease examined in each case. The following fundoscopic macular variants may be 
present throughout the disease process in eyes with MacTel Type 2: 
 
 Reduced retinal transparency, or ‘retinal greying,’ in the parafoveal retina is 
possibly the first funduscopically visible sign. Although the pathophysiology of 
this is yet to be determined, it is unique to MacTel Type 2 and may result from 
extracellular and possibly intracellular oedema or structural changes within the 
neurosensory retina.     
 Reduction or absence of the foveal reflex is common and often apparent early in the 
disease. 
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 Crystalline deposits, which can be found in almost all stages of the disease, are 
located on the anterior surface of the retinal nerve fiber layer and arranged along 
the nerve fibers. Sallo et al.18 hypothesized that crystals originate in the footplates 
of the Müller cells surrounding the nerve fiber bundles. Clemons et al.5 reported a 
prevalence of crystalline deposits in 21% of the population with MacTel Type 2, 
however the prevalence has been reported to be as high as 68%19. 
 Commonly visible in the third stage of the disease, mildly ectatic capillaries were 
reported by Gass and Blodi to be present in 64% of eyes1. Yanuzzi and co-workers4 
noted telangiectatic vessels in both the inner and outer retinal circulatory systems, 
redefining the initial classification in which the vascular abnormalities were 
reported to affect only the inner, deep, capillary network1.  
 Another key feature of MacTel Type 2 are blunted and slightly dilated venules 
extending at right angles into deeper retinal cells. The venules can appear solitarily 
or there may be several of them and are associated with ectatic capillaries or 
pigment hyperplasia in later stages of the disease. It has been postulated that they 
become dilated due to increased blood flow in the paracentral telangiectatic 
capillaries20.  
 Retinal pigment plaques usually occur adjacent to the areas of blunted venules, 
commonly near the tip of the right angle1. They are most likely formed due to 
intraretinal migration of retinal pigment epithelial cells, having originated in areas 
of outer retinal atrophy. 
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 Full thickness macular holes have been reported in a small proportion of patients 
with MacTel Type 22 21-23. Confirmed via OCT imaging, they are believed to develop 
as a result of atrophic changes within the neurosensory retina, specifically a 
derangement of Müller cells. 
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1.1.4  Imaging and Functional Studies: 
 
1.1.4.1  National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) 
 
Used as a measure of health-related quality of life assessment (HR-QoL), the 
multicentre global MacTel Type 2 project administered the National Eye Institute 
Visual Function Questionnaire (NEI-VFQ-25) to patients in an observational natural 
history study24. The 25 question survey asks the respondents to self-evaluate their 
perceived level of vision and its impact on undertaking activities along with the 
psychological implications.  
 
Participants in the MacTel Type 2 study reported significantly reduced HR-QoL 
values in all subscales, with the exception of colour vision, when compared to the 
normal controls (p < 0.0001) and also with other eye diseases with similar visual acuity 
levels. Results confirmed the suspicions that despite relatively good central visual 
acuity, MacTel Type 2 has a significant effect on the health related quality of life 
because many patients have dense paracentral blindspots in each eye even when their 
central vision is relatively normal24. 
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1.1.4.2  Visual Acuity 
 
Central visual acuity is usually unaffected in the early stages of MacTel Type 2. The 
global MacTel Type 2 project5 reported the mean visual acuity in 522 untreated eyes 
as 6/12 (71 letters on a Logarithm of Minimum Angle of Resolution [LogMAR] visual 
acuity chart) with the better eye achieving a mean of 6/9 (75 letters) and the worse eye 
6/15 (65 letters). 58% of the participants had a disease classification of stage 4 or 5 and, 
as expected, the level of visual acuity reduced as the disease severity increased (stage 
0/1: 82 letters, stage 2: 73 letters, stage 3: 73 letters and stage 4: 68 letters [p < 0.01]).  
Gass and Blodi reported similar visual acuity findings, most patients only became 
symptomatic in the 3rd to 4th stage of the disease with some stage 4 patients 
maintaining good visual acuity1.  
 
Eyes progressing to stage 5 MacTel Type 2 are uncommon. The MacTel Type 2 project 
is the only study of its kind which is prospectively assessing the natural history and 
progression of visual acuity associated with the disease however the prevalence of 
eyes which have progressed to stage 5 has not yet been reported. In 2002 Engelbrecht 
et al. retrospectively assessed the final visual outcome of 26 MacTel Type 2 eyes which 
had advanced to stage 525. The authors noted that 21 of the 26 eyes (80%) had a visual 
acuity of 20/200 or worse.  
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1.1.4.3  Fluorescein Angiography 
 
Fluorescein angiography (FA) is a helpful clinical assessment in making the diagnosis 
and mapping the progression of MacTel Type 2. Prior to the introduction of fundus 
autofluorescence (see section 1.1.5.6) and based on the work of Gass1 2, FA was 
regarded as the gold-standard in providing a definitive diagnosis of the disease. In 
Gass’ original classification of the MacTel Type 2 late stage hyperfluorescence in the 
temporal macula helped define the disease in its earliest stages1.  This early late stage 
hyperfluorescence, in most cases, does not involve the central foveal region.  
 
Clemons et al. reported in the baseline findings from the global MacTel project that 
89% of participants showed signs hyperfluorescence with 51% at the level of the 
retinal pigment epithelium (RPE)5. The authors also noted several locations of leakage, 
primarily the RPE or at the level of the capillary network. This variation was shown 
to have a significant impact on the level of vision (Inner capillary network: 65 letters, 
RPE 69 vs absent: 74 letters; p-value 0.03 and < 0.01 respectively) 
 
1.1.4.4  Microperimetry 
 
By mapping the retinal sensitivities of the macula, microperimetric assessment 
provides an improved assessment of the functional defects throughout the disease 
process. Charbell Issa et al. found that the depth of the scotoma present in MacTel 
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Type 2 correlated positively with the disease stage26. Eyes with early stage MacTel 
Type 2 often had preserved retinal sensitivities whilst eyes in the later stages of the 
disease (stages 4 and 5) always showed absolute scotomas corresponding to 
photoreceptor loss in the temporal and infero-temporal macula. Visual acuity 
correlated well with central foveal thresholds however not with the parafoveal 
sensitivities. Thus microperimetric assessment is potentially a more sensitive indicator 
of the visual dysfunction in MacTel Type 2 than central visual acuity. 
 
1.1.4.5  Optical Coherence Tomography (Features of MacTel Type 2) 
 
The introduction and continual advances in Optical Coherence Tomography (OCT) 
has resulted in a greater understanding of the pathophsyiology of MacTel Type 2, 
stressing a neurodegenerative component that is the likely cause of loss of vision. This 
non-contact, cross-sectional, in vivo imaging device has become a valuable tool for 
diagnosing and studying MacTel Type 2 patients. OCT studies of MacTel Type 2 may 
reveal inner retinal cavitation, absence of cystoid macular oedema and increased 
reflectivity of the outer nuclear layer9. OCT also may demonstrate foveal thinning due 
to photoreceptor death which some believe may be secondary to loss of trophic 
support from Müller cell dysfunction27. 
 
Disruption of the inner segment – outer segment (IS/OS) junction of the 
photoreceptors is one of the most common OCT findings in eyes with MacTel Type 2. 
The break is present in the early stages of the disease and typically starts in the 
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temporal foveal region. In advanced cases it can extend to the fovea. Gaudric et al. 
reported that visual function can remain unimpaired despite the presence of a break 
in the IS/OS junction line as long as it does not involve the foveal centre28. Moreover, 
the presence of the break does not necessarily mean photoreceptor loss but may rather 
reflect a change in its structure. 
 
A recent publication from Sallo et al. reported that the disruption and rate of 
progression of the IS/OS junction layer break in MacTel Type 2 showed a significant 
correlation (p < 0.01) with functional microperimetric assessment (see section 1.1.5.3)29. 
The authors suggested that en face OCT imaging of defect in the IS/OS junction layer 
may provide a more accurate means to measure functional progression than VA 
which could be used in any future therapeutic or other interventional trials.  
 
 
Image 1: Spectralis OCT (Heidelberg Engineering) of a stage 3 MacTel Type 2 patient with a 
disruption of IS/OS junction layer (marked by the red lines) in the left eye. Note the break is 
predominately in the temporal parafoveal region. Best corrected, central, visual acuity 20/40. 
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Yanuzzi et al.4 incorporated the OCT in their revision of the classification of the disease 
developed by Gass and Blodi in 1993 referred to above1. In a case series of 26 
participants with MacTel Type 2, they were able to document the presence of inner 
lamellar cysts, which had previously been reported without the advantage of OCT 
imaging, as lamellar retinal holes2. These hyporeflective cavities, often located in the 
foveal pit, show no fluorescein leakage on angiography, in contrast to exudative 
diseases of the macula such as diabetic retinopathy. Furthermore, Barthelmes et al. 
demonstrated that the reflectivity of the cavities in MacTel Type 2 was lower than 
cysts caused by exudative processes30. These findings strengthen the notion that the 
hyporeflective cavities seen in MacTel Type 2 are due to degenerative changes rather 
than an exudative process. 
 
 
 
 
 
 
 
 
Image 2:  Cirrus OCT  (Zeiss Technologies) of a stage 3 MacTel patient demonstrating a hyporeflective 
cavity (marked by red arrow) in the inner retina of right eye. Visual acuity is 20/63 
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1.1.4.6  Fundus Autofluorescence Imaging 
 
Lutein and zeanxanthin are two caratenoids found at high densities within the 
macula, together comprising the macular pigment. They have been shown to 
accumulate in the axons of the cone photoreceptors.31 32 Although their function is not 
entirely clear, it has been postulated that they may act as blue-light filters to reduce 
glare, minimize chromatic aberration and enhance contrast33. They may also act to 
neutralise reactive oxygen species34. Fundus Autofluorescence imaging uses the 
autofluorescent properties of lipofuschin which absorbs light at 460nm and then emits 
it at 488nm. Macular pigment may be visualized in the central macula since it blocks 
the background autofluorescence that emanates from the underlying retinal pigment 
epithelium (RPE).  
  
 
 
 
 
Image 3:  FAF image obtained at 488 nm of a normal eye (left) of a 57 year old woman and of a 57 year-
old woman with MacTel type 2 (right). The eye with MacTel Type 2 has a hyperreflectivity in the central 
macular region in comparison to the normal eye. This is related to a reduction or absence of macular 
pigment which is typical throughout the MacTel Type 2 disease process. 
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Autofluorescence studies have identified alterations in the distribution of macular 
pigment to be a sensitive and relatively specific feature of MacTel type 235. While the 
distribution of macular pigment within the macula can vary significantly amongst the 
normal population36-38, Helb et al. noted reduction of macular pigment density in the 
temporal perifovea of subjects with MacTel type 2 which extended out to 6 degrees 
temporally39. This discovery is consistent with other morphological findings including 
a reduction in retinal transparency, presence of crystals and right-angled venules, first 
postulated by Gass and Blodi1. 
 
1.1.5  Treatment  
There have been several approaches to the treatment of MacTel Type 2. However, the 
uncommon nature of the condition together with difficulty in measuring progression 
over a 1-2 year period means that planning randomised, controlled clinical trials is 
difficult. Thus the literature reports small, retrospective case-series or single 
observations.  
1.1.5.1  Nonproliferative Stage  
1.1.5.1.1 Argon Laser Photocoagulation 
 
Several studies have reported significant improvements in best corrected central 
visual acuity following treatment with argon laser photocoagulation13 40. However, the 
vast consensus throughout the literature is now that there is no substantial evidence 
to support its use1 41-43.  Kiraly et al. examined the progression of VA amongst a cohort 
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of 13 patients with MacTel Type 243. Six patients were treated with argon laser 
photocoagulation and compared with those who were treatment-naïve.  The mean 
visual acuity of both groups deteriorated over the follow-up period (mean 38 months) 
from 71 letters to 61 letters with no significant difference observed amongst the 
groups. Other reported findings following photocoagulation therapy in MacTel Type 
2 include increased retinal pigment epithelial changes, postoperative retinal vascular 
distortion, vascularised retinal scars, postoperative retinal hemorrhages and 
subretinal hemorrhages41 44. Since there is no proven benefit and possibly an increased 
risk of advancing to the proliferative stage, the use of argon laser photocoagulation 
for non-proliferative MacTel Type 2 has largely been abandoned.  
 
1.1.5.1.2 Intravitreal Triamcinolone Acetate 
 
Intravitreal Triamcinolone Acetate (IVTA) has been used in a small number of cases 
in MacTel Type 2 patients with varying results45-48. Improvements in late stage 
fluorescein angiography hyperfluorescence have been noted. Whilst Martinez 
reported an improvement in the VA of more than 2 lines of vision47, other studies did 
not record any significant improvement in the final visual outcome45 46. Moreover, 
Smithen and Spaide reported that 6 weeks following IVTA treatment neither VA nor 
FA findings showed any sign of improvement49. Cakir et al. reported a reduction of 
central macular thickness (CMT), with the effects of IVTA appearing to diminish at 
the 9-month follow-up examination. 
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1.1.5.1.3 Vascular Endothelial Growth Factor Inhibitors 
 
Anti vascular endothelial growth factor (anti-VEGF) agents such as Bevacizumab have 
been used in short-term observational studies. Charbel Issa examined a case series of 
6 eyes treated with the anti-VEGF medication bevacizumab50 and noted an increase in 
mean VA and a reduction in both CMT and late phase FA leakage. However, in 
accordance with the chronic nature of MacTel Type 2, long-term follow up revealed 
that the effects of anti-VEGF treatment began to dissipate after 3-4 months51. Anti-
VEGF agents such ranibizumab have been proven to be safe in patients with age-
related macular degeneration for periods up to 2 years whilst undergoing a 4 – 6 
weekly dosing regimen52 53. However, due to the relatively recent history of 
intravitreal anti-VEGF agents there is limited long-term safety data, thus for chronic 
conditions such as MacTel Type 2 the safety profile is uncertain. 
 
It has also been suggested that VEGF plays a role in photoreceptor differentiation and 
survival as well as maintaining homeostasis of the retinal vasculature54. Thus 
sustained use of anti-VEGF agents may be neurotoxic and cause accelerated apoptosis. 
As MacTel Type 2 has been hypothesized to have both vascular and 
neurodegenerative properties27 long-term use of an anti-VEGF agent may be 
contraindicated.  
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1.1.5.2   Proliferative Stage 
 
Although uncommon, the development of subretinal neovascularisation (stage 5 in 
the disease progression) represents a major cause of visual loss in MacTel Type 21 4 25. 
In a case series of 26 eyes with stage 5 MacTel Type 2, Engelbrecht et al. noted that 
final visual acuity in 80% of the cohort was 20/200 or worse.25 
 
 
 
1.1.5.2.1  Photodynamic Therapy  
 
 
Although used sparingly, photodynamic therapy (PDT) has been reported in several 
cases of MacTel type 2. The first documented use of PDT with Verteporfin for MacTel 
Type 2 was reported by Potter et al. in 200255. In the authors single case series, VA 
improved by approximately two lines (20/70-2 – 20/50-2) after two sessions and the 
benefit remained stable over a follow up period of seven months. Importantly, the 
authors noted that although the PDT effectively treated the neovascular membrane 
the characteristic parafoveal leakage typical in MacTel Type 2 continued55. 
 
Potter et al. conducted the largest case series of PDT in MacTel Type 2 with 
retrospective analysis of 7 eyes in 6 patients56. Baseline VA was 20/80 (range 20/40 – 
20/400) and after a mean of 2.4 treatments only one eye had a significant decrease in 
22 
 
VA (2 or more lines) whilst the other 6 eyes remained stable. There was no significant 
difference in the mean, final VA measurement to that recorded at baseline.  
 
Snyers et al. reported their findings from 4 patients with neovascular MacTel Type 2 
treated with PDT. They found that in three patients baseline VA remained stable 
(20/30 – 20/40) after one, two and three sessions of PDT within follow up periods of 
23, 21 and 9 months respectively57. In the fourth eye the leakage persisted and the VA 
regressed from 20/50 to 20/200 after 4 treatments. 
 
1.1.5.2.2  Intravitreal VEGF Inhibitors 
 
The application of intravitreal VEGF inhibitors now forms the first line of treatment 
for choroidal neovascular membranes due to age-related macular degeneration 
(AMD) 52 58 59. The concept of a similar pathogenesis of AMD and MacTel Type 2 was 
the rationale to study the impact of VEGF inhibitors as a potential treatment option 
for proliferative MacTel Type 250 60-63.  
 
The first reported use of anti-VEGF to treat neovascular MacTel Type 2 was from Jorge 
et al. who observed an improvement in BCVA of 2 lines (20/40 – 20/20) over a 24 week 
period.61 The improvement in VA noted by Jorge et al. is consistent with 4 other 
reports which show positive benefits of intravitreal anti-VEGF therapy for 
proliferative (stage 5) MacTel Type 251 60 61 64.   
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1.2  Obstructive Sleep Apnoea 
 
1.2.1   Background: 
 
Obstructive sleep apnoea (OSA), which refers to the partial or complete collapse of the 
upper airway during sleep, is commonly associated with a reduction in blood oxygen 
saturation65 66. The characteristic sleep pattern for the syndrome is a period of loud 
snoring followed by intermixed periods of silence, often lasting for 20-30 seconds. 
Typically, the patient has a history of snoring, often from childhood, at an intensity 
which disturbs bed partners or those in close proximity65. The level of snoring is often 
exacerbated following the consumption of alcohol67 or increased body mass.  
 
Due to the cyclic repetition of the apnoeic events and the associated interruptions to 
sleep, sufferers often report symptoms of chronic daytime sleepiness. The episodes of 
daytime sleepiness tend to be heightened during periods of relaxation. In serious cases 
patients may fall asleep whilst engaged in active activities such as eating, walking or 
driving65  When sufferers do have naps during the day they often wake feeling un-
refreshed, coupled with a mild, general headache. Other post-sleep symptoms include 
disorientation, grogginess, mental dullness and coordination imbalance65.   
 
There are two distinct episodes, apnoeas and hypopnoeas, which occur during the 
sleep cycle of an individual with obstructive sleep apnoea syndrome. An apnoea, as 
defined by The American Academy of Sleep Medicine (AASM) in the 2006 update of 
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The International Classification of Sleep Disorders – diagnostic and coding manual, is 
the “cessation of airflow at the nostrils and mouth lasting at least 10 seconds”65. A 
hypopnoea is a partial obstruction of respiratory tract and is defined as “a reduction 
in airflow greater than 50% [from baseline] which is associated with a reduction in 
blood oxygen saturation levels”65. 
 
The Apnoea-Hypopnoea Index (AHI) is the principal measure for quantifying disease 
severity. The index is a count of the number of apnoeas or hypopnoeas per hour. Prior 
to the updated classification provided by the AASM, and despite its importance, there 
were varying definitions regarding the reduction in airflow required to constitute a 
hypopnoea. One striking study was undertaken by Moser et al., in which they 
examined the criteria used to define a hypopnoea: they reported that across the 45 
accredited sleep centres surveyed no two centres had the same definition of 
hypopnoea. They recommended, therefore, that a universal standardization needed 
to be established68. A number of reports 69-72 have looked at the effect of the varying 
differences in hypopnoea definition and the importance of producing a standardized 
definition to produce more consistent disease diagnosis and severity grading along 
with reduced inter-clinical variation70 73-75.  
 
In light of these publications, the AASM produced a consensus report in 1999 where 
they described 2 types of hypopnoeas: those with a greater than 50% decrease in 
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airflow without associated oxygen desaturation and those with a lesser airflow 
reduction in association with oxygen desaturation of >3% or an arousal76. 
1.2.2  Pathophsyiology 
 
The primary anatomical region for an apnoeic episode emanates from an obstruction 
of the pharynx. Unlike other areas of the respiratory tract, which are supported by 
fibrous connective tissues and bone, the lumen of the pharynx is supported by skeletal 
muscle and smooth tissues in order to enable the range of kinetic movements that are 
required for speech, chewing and swallowing77 78. Stimulation by the sympathetic 
nervous system of the pharyngeal smooth muscle drops during sleep, causing it to 
become flaccid which, in the case of OSA results in the obstruction of the airway. With 
arousal, the sympathetic nervous system stimulates the pharyngeal smooth muscle, 
increasing the patency of the pharynx. 
 
Other anatomic factors such including retrognalia, tonsillar hypertrophy and 
craniofacial abnormalities have been reported as causative region for obstructive sleep 
apnoea79-81. It is believed that these factors induce OSA through the increased  
susceptibility of the upper airway collapsing during sleep82.  
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1.2.3  Epidemiology 
 
Obstructive sleep apnoea prevalence estimates throughout the literature show 
significant variations. This may be, in part, due to varying methodologies that 
epidemiological studies have undertaken. Methodologies include the use of gold-
standard in-laboratory overnight polysonography and home-based unattended 
overnight portable devices, through to self-reported evaluations for markers for OSA.  
 
Young et al. reported that the prevalence of undiagnosed sleep disordered breathing 
of 5 episodes or more per hour (AHI ≥ 5) was 24% and 9% amongst male and females 
of middle age, respectively83. In order to establish the minimum criteria required to 
constitute obstructive sleep apnoea the authors included data on hypersomnolence 
and produced a final prevalence estimate amongst middle aged male and females of 
4% and 2% respectively.  
 
In an epidemiological study of 4,364 men and 12,219 women aged between 20 and 100 
Bixler et al. reported a similar prevalence to that of Young and co-workers84 85. Using 
a disturbance index of 10 or more episodes per hour (AHI ≥ 10) as the minimum 
criteria, Bixler and co-workers reported a prevalence amongst middle aged males and 
females of 3.9% and 1.2% respectively. The authors also concluded that the prevalence 
appeared to increase with age, however with age the severity of the apnoeic events 
decreased.  
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1.2.4  Screening Questionnaires 
 
A monitored overnight polysonography examination remains the gold-standard for 
the diagnosis of obstructive sleep apnoea. However, these devices are often in limited 
supply, labor intensive and expensive. Also, the sick or elderly can find the devices 
uncomfortable and may be reluctant to undergo assessment. These factors have seen 
the introduction of screening questionnaires which provide a quick, cost-effective way 
of establishing the risk for sleep disordered breathing. The most common surveys are 
the Berlin Questionnaire (BQ) and Epworth Sleepiness Scale (ESS.)  
 
The subjective nature of screening questionnaires can often give rise to inaccurate 
results. For example, the subject may be unaware of the symptoms giving rise to a 
false negative. Kumru et al. looked at the variability of ESS scores by having the 
patient and bed partner complete the survey regarding their own perception of the 
patients level of sleepiness86. They reported that the patient consistently recorded a 
lower ESS value (11.1 ± 5.4) when compared to evaluation from the partner (12.3 ± 5.1) 
(p = 0.025.) 
 
1.2.4.1  Berlin Questionnaire 
 
Using questions developed from the literature pertaining to known factors, co-
morbidities and behaviors related to sleep apnoea, the Berlin Questionnaire was 
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established as an outcome of the 1996 Conference of Sleep in Primary Care. The 
questionnaire comprises three categories designed to evaluate the presence and 
patterns of snoring, daytime fatigue or sleepiness, along with the co-morbidities of 
hypertension and obesity. Although not directly questioned, anthropometric data 
allows for obesity status to be established through the calculation of the Body Mass 
Index (BMI) derived by dividing weight (kg) by the square of the height (m). A subject 
is defined as obese if the BMI is equal to, or greater than, 30kg/m2. 
 
Each category is evaluated as either ‘positive’ or ‘negative’ based on the persistence 
or frequency of symptoms. If two or more categories are defined as positive then the 
participant is regarded as high risk for sleep apnoea syndrome. 
 
The validity of the Berlin Questionnaire was first analysed by Netzer et al. in 199987. 
The questionnaire was administered to 1008 participants: of the 744 (74%) respondents 
100 were randomly selected for overnight polysonography evaluation. The authors 
found that being in the high-risk group predicted a respiratory disturbance index of 5 
with a sensitivity of 0.86 and a specificity of 0.77, concluding that the questionnaire is 
an effective screening tool for those likely to have sleep apnoea87. 
 
In contrast to the positive findings of Netzer, Friedman et al. retrospectively analyzed 
the medical records of 223 consecutive patients in order to assess, amongst other 
factors, the sensitivity and specificity of the Berlin Questionnaire88 in predicting an 
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Apnoea Hypopnoea Index (AHI) of ≥5. The authors noted a much lower sensitivity 
and specificity, of 0.615 and 0.226 respectively, to that of Netzer and concluded that 
the Berlin Questionnaire alone was not sensitive or specific enough to accurately 
diagnose sleep apnoea syndrome88.  
 
1.2.4.2  Epworth Sleepiness Scale 
 
For those with sleep apnoea excessive sleepiness is a typical presenting complaint. The 
sleepiness is usually most evident when the patient is in a relaxing situation, such as 
when sitting reading or watching television89. The Epworth Sleepiness Scale (ESS), (see 
Appendix 4.2) another self-administered questionnaire, developed in 1990 at the Sleep 
Disorders Unit at the Epworth Hospital in Melbourne, is common screening tool 
designed to subjectively quantify the level of daytime sleepiness. 
 
The scale uses 8 questions to evaluate a respondent’s propensity to doze or fall asleep 
under certain circumstances. The responses are graded as either no chance, slight, 
moderate, or high and a total score of greater than, or equal to, eleven (11) out of a 
possible twenty-four (24) is considered a positive predictor for OSA90. 
 
The reliability and validity of questionnaires as effective screening tools is the subject 
of a contentious and ongoing debate. Chung et al. demonstrated in a cohort of Chinese 
participants that the ESS values for OSA patient was significantly higher when 
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compared with a control group. The mean ESS in the OSA population was 13.2 against 
7.5 for the control (p < 0.001)91. However, the criticism of the ESS is that although 
sensitive for OSA it is not specific, as the causality of the daytime somnolence can 
often be attributed to other factors such as those who are sleep deprived. In a 
community based study of four hundred and forty one (441) subjects, Olsen et al. 
reported high ESS values in 41% of those with OSA but also in 37% of snorers without 
OSA and 37% of non-snorers92. 
 
1.2.4.3  ResMed ApneaLink™ 
 
The ResMed ApneaLink™ (ResMed Corporation, Poway, California, USA) is a 
multichannel, objective screening tool for OSA. The device consists of a nasal cannula 
and pulse oximeter attached to a housing unit worn around the users’ chest. The 
device is battery powered with a sampling rate of 100Hz and 15Mb of storage 
capability providing enough storage for approximately 10hrs of recording time.   
 
Several studies have been undertaken to establish the reliability of the ApneaLink™ 
device as an effective screening tool for obstructive sleep apnoea93-98. The 
methodologies of the studies were similar in that the ApneaLink™ recordings were 
undertaken simultaneously with overnight polysonography measurements. In 
accordance with the disease profile the studies had a male dominated cohort with ages 
ranging from the 5th to 8th decade. The literature reports that the ApneaLink™ 
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provides a sensitivity and specificity for an AHI greater than or equal to ten (10) 
ranging from 91.0 - 97.7% and 87.5 – 100% respectively93-97. Moreover, the results 
suggest that the ApneaLink™ is both sensitive and specific to diagnose moderate to 
severe sleep apnoea.  
 
1.2.5  Association with Retinal Disease 
 
 
1.2.5.1  Central Retinal Vein Occlusion 
 
The central retinal vein is the primary pathway for venous drainage of the eye. The 
vein exits the eye via the optic nerve where it shares a common sheath with the central 
retinal artery. It is believed that hypoxia associated with apnoeic events leads to 
vasodilation and an increase in intracranial pressure. The increase in intracranial 
pressure can lead to papilledema, increasing the venous pressure within the nerve. It 
has been suggested that this slowing of retinal circulation may contribute to the 
pathogenesis of retinal vein occlusion.99 
 
In a case study of three patients with retinal vein occlusion, confirmed obstructive 
sleep apnoea and an absence of vasculopathy, Leroux les Jardins et al. postulated that 
the sequelae of hypoxemia and elevated intracranial pressure from OSA results in an 
impairment of retinal blood supply99. This impairment may, together with other 
factors, cause oxidative stress, vascular endothelial dysfunction, inflammation, and 
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metabolic down-regulation. The authors concluded that although obstructive sleep 
apnoea is another potential risk factor for retinal vein occlusion, further investigation 
needs to be carried out to confirm the hypothesis.  
 
Glacet-Bernard et al. in 2010 further explored an association between obstructive sleep 
apnoea and retinal vein occlusion by prescreening 63 consecutive retinal vein 
occlusion patients for signs of OSA100. The authors were looking for participants who 
showed signs of a minimum two of three co-morbidities of OSA: cardiovascular 
disease, snoring and daytime sleepiness (defined with the ESS equal to or greater than 
10). Of the 63 prescreened, 30 (47%) fulfilled the criteria and underwent overnight, in 
hospital, respiratory polysonography. Data analysis confirmed that 23 (37%) had 
obstructive sleep apnoea to some degree.  As the screening questionnaires and co-
morbidities are not a definitive marker for OSA, having all participants, independent 
of screening classification, undergo sleep analysis would provide a more definitive 
estimate of the prevalence of sleep apnoea in the population with retinal vein 
occlusion. However, if those who were excluded after screening were presumed not 
to have OSA, then having them undergo overnight assessment would result in a false 
negative rate which would only serve to increase the prevalence estimate. The 
increased prevalence of sleep apnoea in this study is significantly higher than that 
reported for the general population (see above).  Thus the study supports the 
hypothesis of Leroux les Jardins et al. that retinal vein occlusion is a risk factor for 
those with OSA.  
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1.2.5.2  Central Serous Chorioretinopathy 
 
In 2007 Leveque et al. reported that patients with Central Serous Chorioretinopathy 
(CSCR) were at increased risk of OSA when compared to a control group (odds ratio 
= 3.67, 95% CI; P = 0.0046)101. The investigators retrospectively contacted potential 
participants with a confirmed diagnosis of CSCR and administered the Berlin 
Questionnaire with age- and sex-matched controls used as the comparators. Although 
the Berlin Questionnaire has been proven to be both sensitive and specific for 
moderate to advanced cases of OSA this single stage methodology can only provide, 
at best, a weak association. To confirm a positive association an objective, prospective 
study would be advantageous. 
 
1.2.5.3  Diabetic Macular Oedema 
 
Using the ResMed ApneaLink™ Mason et al. recently reported an association with 
sleep disordered breathing and diabetic macular oedema (DMO)102.  Of 195 
participants approached 80 (40 male) participated in the study. The average age of 
participants was 64.7 (SD 11.7) years and mean BMI was 30.2 (SD 6.2) kg/m2. Although 
the authors noted an increased prevalence in the oxygen desaturation index (ODI) 
(ODI ≥10 = 54%) and AHI (31% ≥ 15) the study lacked adequate control data and, 
coupled with the relatively low response rate (41%) which is likely to induce 
nonresponse bias,  the reported association between DME and SDB should interpreted 
with caution.  
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Interestingly the authors noted that the ESS values of the respondents was 7.4 (SD 4.8) 
which represents a value that is within normal limits (≥10 clinically significant) and 
did not correlate with either the AHI or ODI.   
 
1.2.6  Treatment 
 
Continuous Positive Airway Pressure (CPAP) is widely accepted as the treatment of 
choice for obstructive sleep apnoea103. As the primary cause of apnoea episodes is the 
obstruction of the orophayngeal pathway, the treatment relies on the steady stream of 
pressure from a control box preventing the closure of the upper airway. 
 
Clinically, CPAP has been shown to effectively reduce  respiratory disturbances along 
with the AHI and is more effective than other methods of treatment including 
conservative management and nocturnal positional therapy104-111.  
 
It has generally been reported that with CPAP the symptoms of daytime sleepiness, 
measured using the ESS, appear to significantly reduce105 111-118. Interestingly however, 
there is no perceived improvement in quality of life assessment with both positive111 
112 116 119 and negative113 118 120 changes in QoL scores reported.  
 
A small pilot study of the benefit of supplemental oxygen supply for diabetic macular 
oedema has been reported121. Nine eyes of nine patients showed a reduction in the 
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central macular thickness on OCT examination when compared to pre-treatment 
levels after three months of persistent nocturnal oxygen supplementation (P < 0.0077). 
Four of these nine eyes also showed a significant improvement in BCVA (greater than 
5 letters on LogMAR vision scale) thus suggesting the potential visual benefit of 
maintaining stable oxygen saturation levels throughout the sleep cycle. 
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1.3  Müller Cells 
 
Spanning the entire thickness of the retina, Müller cells are the primary glial cell in the 
mammalian retina. The Müller cell soma is located in the inner nuclear layer (INL), 
with two trunks spanning in opposite directions. The outer trunk extends to the 
photoreceptors where it forms the outer limiting membrane, from which microvilli 
extend as far as the retinal pigment epithelium (RPE). The inner truck extends as far 
as the vitreous where it forms the inner limiting membrane. Both trunks have 
processes which encompass retinal neurons, synapses and blood vessels. Dubois-
Dauphin et al. highlighted the importance of Müller cells in maintaining retinal 
homeostasis after selective Müller cell destruction through the over expression of the 
human Bcl-2 protein resulted in retinal dysplasia, photoreceptor apoptosis, along with 
retinal degeneration and proliferation of the retinal pigment epithelium (RPE)122.  
 
Glial cells, including astrocytes, oligodendrocytes and ependymal cells, undertake 
roles in partnership to enable the ongoing functioning of neuronal processes in other 
locations within the central nervous system. As Müller cells are the primary glial cell 
of the retina they have the ability to perform all of these process individually. One 
crucial role of the Müller cell is to provide the retinal neurons with nutrients including 
lactate and pyruvate for metabolism123. 
 
In contrast to retinal neurons, Müller cells are relatively resistant to various noxious 
stimuli such as ischemia, hypoxia and hypoglycaemia124. Winkler et al. found that 
37 
 
Müller cells were able to maintain their level of adenosine triphosphate (ATP) 
aerobically for 4 hours in both the presence and absence of glucose125. These authors 
also noted that ATP content was maintained anaerobically at similar levels to that of 
aerobic metabolism, but only in the presence of glucose. They concluded that Müller 
cells obtain their ATP primarily from glucose and have a low rate of oxygen 
consumption. In other words, Müller cells produce energy through the glycolytic 
pathway, which only functions in other tissues under anaerobic conditions, in an 
aerobic environment. As the photoreceptors are the highest energy consuming tissue 
(per gram) within the body126 this metabolic manoeuvre may be undertaken to make 
more oxygen available for the surrounding photoreceptors and neurons which 
produce energy by aerobic metabolism through oxidative phosphorylation. This dual 
metabolic mechanism may also explain why Müller cells are less susceptible to 
ischemia or hypoglycaemia than neurons as was first reported by Bringmann et al.124.  
 
Glutamate is the primary excitatory neurotransmitter within the mammalian retina. 
Its uptake by Müller cells is essential for ongoing neuronal signaling. Rowan et al. 
reported that with the assistance of GLAST-1, a high affinity transporter, Müller cells 
undertake the majority of glutamate uptake, thus providing an indirect, active role in 
the recycling of neurotransmitters for excitatory transmission within the retina127. The 
clearance of glutamate by Müller cells is also vital to normal functioning of the neural 
retina as impairment of this function within the Müller cell has been reported to result 
in neurotoxicity even in low concentrations128.  This form of neurotoxicity can lead to 
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neuronal dysfunction along with apoptosis of retinal neurons within the diseased 
retina129. 
  
The blood retina barrier is formed by a series of tight junctions between the vascular 
endothelial cells of the retinal circulation. This ensures that the extracellular space of 
the retina is tightly controlled in order to ensure efficient neural activity. There is 
evidence that Müller cells play a pivotal role within the healthy retina in providing 
support to the retinal vascular network including the autoregulation of 
haemodynamics along with the maintenance of the blood retina barrier. Paulson et al. 
reported that, in response to changes in neuronal activity, Potassium (K+) is released 
from the glial endfeet which assists in regulating vascular blood flow130. Like 
astrocytes, it appears that Müller cells are able to induce vascular barrier properties, 
thereby playing a significant role in the development and maintenance of the blood 
retina barrier131.  
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1.3.1  Changes in MacTel Type 2 
 
Although the basic mechanism for the structural and functional alterations seen in 
MacTel Type 2 remains unclear there is evidence to suggest that dysfunction or death 
of the Müller glia plays a role.  
 
One striking report was published by Powner et al. in which the authors histologically 
examined the retina of a 58 year female with MacTel type 227. The most prominent 
feature of the specimen was the depleted expression of specific Müller cell markers in 
the central macula. In the sample, a reduction of macular pigment consistent with 
expected finding in MacTel Type 26 39 was reported and correlated with the area of 
reduced Müller cell staining. Gass first hypothesized that a high concentration of 
macular pigment is located in the “Müller cell cone”, located within the outer limiting 
membrane132. Using the glial selective toxin DL-alpha-aminoadipic in monkeys, Shen 
et al. confirmed Gass’s hypothesis as the injection resulted in ablation of 
photoreceptors, however both Müller cells and macular pigment remained 
unaffected133. Although the function of macular pigment trafficking and storage 
within Müller cells is unknown, these finding suggests that the reduction of macular 
pigment typically seen in MacTel Type 2 may be linked to Müller cell dysfunction.  
 
Powner et al. used the symbiosis between Müller cells and photoreceptors, necessary 
for maintaining retinal homeostasis, to hypothesize Müller cell dysfunction as the 
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primary mechanism that leads to the other clinical features of MacTel Type 2. As the 
healthy Müller cell provides trophic support through the uptake of the neurotoxic 
neurotransmitters glutamate and glutamine124 as well as neuroprotective functions134 
the authors proposed that Müller cell death or dysfunction may result in 
photoreceptor loss which has been documented in MacTel Type 2 through OCT 
findings4 28. This close interaction and subsequent disruption of Müller cells in MacTel 
Type 2 may also account for the other clinical features including cavitation of the inner 
retina through loss of vertical structural integrity or disturbed fluid transport within 
the diseased Müller cells135.  
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Chapter 2: Clinical Study 
Prevalence of Obstructive Sleep Apnoea in a population with Idiopathic 
Macular Telangiectasia Type 2: The SAMTel Study. 
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2.1  Study Rationale 
 
Obstructive Sleep Apnoea (OSA) is associated with significant physiological sequelae 
as a direct result of signature apnoeic / hypopnoeic events, particularly sympathetic 
activation associated with arousals and intermittent hypoxia. This intermittent 
hypoxia (IH) has been implicated as contributing to major co-morbidities associated 
with OSA. Further, associated with these respiratory events is a typical pattern of 
blood pressure change, with transient hypertension associated with the recovery 
breathing after an apnoea or hypopnoeic event. 
 
MacTel Type 2 is a poorly understood, generally untreatable condition that affects the 
central maculae of both eyes. Its prevalence is estimated to be around 1:1000 in the 
Caucasian population over 45, however it is often misdiagnosed, even by 
Ophthalmologists. MacTel Type 2 may lead to progressive loss of central vision. 
Evidence is emerging that warrants further research into whether obstructive sleep 
apnoea may contribute to the development of MacTel Type 2. An increased prevalence 
of sleep apnoea has been reported in other retinal diseases, including central serous 
chorioretinopahy101, diabetic retinopathy102 and retinal vein occlusion99 100.  
 
 
Further, in the one human specimen with MacTel Type 2 that we have obtained, the 
most striking feature was derangement of Müller cells in the central macula27. Since 
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Müller cells may be responsible for supplying lactate to photoreceptors when oxygen 
levels drop, which may occur in OSA since the outer retina is the most metabolically 
active part of the body126, eyes with MacTel Type 2 may be susceptible to 
photoreceptor damage from even mild reductions in blood oxygenation that would 
not be harmful to normal eyes. We postulate that the microvilli of the apical processes 
of Müller Cells sense changes in local oxygen levels which they use to promote aerobic 
or anaerobic metabolism depending on the local oxygen concentration. So defective 
Müller cell function may make a retina more susceptible to damage from modest 
fluctuations in the peripheral oxygen saturation levels (SpO2), such as may be seen in 
people with sleep apnoea, than a retina with normal Müller cell function. 
 
The intermittent hypoxia associated with OSA can be effectively managed by proper 
application of current sleep apnoea therapies, including continuous positive airway 
pressure (CPAP) treatment. Therapy depends on recognition of the obstructive sleep 
apnoea disorder. Obstructive sleep apnoea remains widely under-diagnosed (with 
possibly 80% of OSA patients undiagnosed)136.  As such, if MacTel Type 2 has a high 
association with obstructive sleep apnoea, a treatable condition which is possibly 
contributory to the broader pathophysiology of the patient, management may be 
improved by implementation of screening or diagnosis methods for sleep apnoea in 
the MacTel Type 2 population. 
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2.2  Methods 
 
 
In order to effectively assess the level of sleep disordered breathing amongst the 
sample population it was decided that the case-control pilot study would be 
conducted in two phases. The first, involved the dissemination of a sleep related 
questionnaire to a population with a confirmed diagnosis of Macular Telangiectasia 
Type 2. In the second phase selected participants who had completed phase one were 
asked to wear an overnight sleep analysis device (ResMed ApneaLink™) in order to 
establish if a positive finding from the questionnaire was indicative of a true-positive 
for sleep disordered breathing.  
 
The pilot study was conducted in accordance with the International Conference on 
Harmonisation and Good Clinical Practice (ICH-GCP) regulations and ethical 
approval was granted from the Sydney Local Area Health District, Royal Prince 
Alfred Hospital Medical Centre under approval number HREC/11/RPAH/642. The 
research was also ratified by the Human Research Ethic Committee of the University 
of Sydney (ref IM/KR). 
 
The sample of selected participants were selected from those currently enrolled in the 
Natural History and Observation Registry (NHOR) study as part of the global MacTel 
project (https://web.emmes.com/study/mactel/). All participants were selected from a 
single site, The Save Sight Institute, University of Sydney who has the largest cohort 
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of participants in the global project. Potential participants needed to be over the age 
of eighteen and have a confirmed diagnosis of Idiopathic Macular Telangiectasia Type 
2 as confirmed by the Moorfields Reading Centre, the central reading centre for the 
global MacTel Type 2 project, located within the Moorfields Eye Hospital, London, 
United Kingdom.  
 
The questionnaire used in phase one of the study (appendix 4.3) was developed with 
the assistance of the Sleep and Circadian Research Group at the Woolcock Institute of 
Medical Research under the guidance of Professor Ron Grunstein and Dr Nathaniel 
Marshall. The questionnaire incorporates basic health and anthropometric data along 
with the Berlin Questionnaire and the Epworth Sleepiness Scale both of which are 
validated screening questionnaires for sleep disordered breathing.  
 
Once final ethical approval had been granted the questionnaire along with a copy of 
the approved cover letter, participant information sheet and informed consent 
document were mailed to all potential participants along with return postage material. 
After a response period of several weeks it was decided that a second mail out should 
take place in order to increase the sample size and also to reduce the risk of selection 
bias as those who have symptoms consistent with sleep disordered breathing are more 
likely to respond rather than those with no symptoms.  
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Throughout the course of the first phase several potential participants presented to 
the clinic as part of their annual review for the NHOR study. Those from whom a 
response had not been received were approached during this visit to determine if 
there was an expression of interest. For those interested, the study was explained and 
all relevant questions answered. Participants were asked to complete the 
questionnaire whilst in the clinic. For those not interested no further action was taken 
and this did not affect the standard of care they received as part of the NHOR study.  
 
Hard copies of the phase one results along with the signed informed consent 
documentation were stored in A4 ring binders in a locked office. The results were 
collated into a central database to enable electronic data analysis.  
 
To follow-up on the questionnaire a subsection of these participants were selected to 
undertake an overnight sleep analysis using the ResMed ApneaLink™, a portable 
home based unit. This was performed to confirm if a positive finding from the 
questionnaire was indicative of true sleep apnoea.  The device is worn around the 
user’s chest over the top of sleep attire.  The multichannel device is able to record the 
presence of apnoeas or hypopnoeas along with breathing and snoring data through a 
nasal cannula. Oxymetry and pulse data is recorded through the application of a 
finger sensor.  
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For the purposes of this study four ApneaLink™ devices were provided under an 
agreement with the ResMed foundation.  
 
Due to the limited number of devices and the estimated extensive turnaround time of 
each device it was determined that a smaller sample size would be collected for this 
phase of the study. To enable significant analysis 30 participants were required to 
undertake the ApneaLink™ recording. Participants for this phase of the study were 
selected sequentially from those with pending NHOR MacTel Type 2 outpatient study 
visits. This would provide an effective randomization method as there is no sequence 
to the timing of their visit as well as being completely independent of results gathered 
from phase one. This method also allowed the investigator to effectively demonstrate 
how to correctly apply and operate the unit along with potential trouble shooting 
information. Participants were given appropriate postage supplies to ensure the safe 
return of the devices.  
 
The Apnoea Hypopnoea Index (AHI) which records the number of apnoea and 
hypopnoea events per hour, was used to grade the severity of sleep disordered 
breathing. An apnoeic event was defined as a cessation of breathing >10 seconds 
whilst hypopnoea was defined as a >50% reduction in airflow coupled with a > 4% 
reduction in oxygen saturation levels (SpO2). The severity of AHI can be graded 
according the number of apnoea/hypopnoea events per hour. The severity is a linear 
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scale with 0 – 5 events is classified as within normal limits, 6 – 20 mild disturbance, 21 
– 50 moderate and greater than 50 episodes per hour graded as severe OSA. 
 
To effectively compare the results attained in the study normative control data was 
acquired from the Busselton Population Medical Research Institute in Western 
Australia. Where possible, MacTel Type 2 participants were matched with up to 3 
Busselton Health Study control participants for age, sex, body mass index (BMI) and 
the comorbidities of hypertension and diabetes. Data was collected on the control 
baseline characteristics along with results from the BQ and ApneaLink™ recording 
device. 
 
Comparison methods of the two populations, including testing for homogeneity and 
equality of means, was performed using chi-square and two sample t-tests. 
Participants were classed as being positive for OSA based on an AHI of >5. Tests for a 
dependent relationship between particular observed variables were performed using 
chi-squared tests for independence. Observed differences were considered using 
analysis of variance. The conventional threshold of 0.05 was used for statistical 
significance throughout. Statistical analysis was performed using R version 2.15.0 
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2.3  Results 
 
 Table 2: Baseline Questionnaire and ApneaLink™ Characteristics 
 
SD (Standard Deviation); M (male); BMI (body mass index)  
 
 
  
 
Questionnaire ApneaLink™  
 MacTel Type 2 Controls MacTel Type 2 Controls 
Participants  57 165 29 83 
Age years (SD) 62.2 (9.6) 62.1 (10.0) 62.4 (8.5)  62.4 (9.2) 
Sex M (%) 19 (33) 55 (33)  7 (24) 19 (23) 
BMI kg/m2 (SD) 29.8 (4.7) 29.4 (4.8) 29.9 (5.3) 29.3 (4.8) 
Hypertension (%) 18 (32) 67 (41) 13 (45) 43 (52) 
Diabetes (%) 12 (21) 19 (12)  5 (17)  10 (12)  
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Table 3: Outcomes from Self-Reported Sleep Questionnaire 
 
 MacTel Type 2 (n = 57) Controls (n = 165) p - value 
Self Reported Snorers (%) 47 (82) 119 (72) 0.27 
Positive BQ* (%)  23 (40) 49 (30) 0.95 
ESS† mean score (SD)  6.4 (5.0) - - 
ESS < 10 (%) 45 (79) - - 
ESS > 10  12 (21)  - - 
*BQ Berlin Questionnaire †ESS Epworth Sleepiness Score. A score > 10 is classed as significant for 
sleep disordered breathing. Values not available for the control cohort.  
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Table 4: Overnight ApneaLink™ measurement in MacTel Type 2 and Control patients 
 
 MacTel Type 2(n=29) Controls (n = 83) p-value 
AHI* mean (SD) 9.6 (14.7) 9.7 (10.8) 0.95 
AHI 0-5 (%) 15 (52) 36 (43) 0.57 
AHI > 5 (%) 14 (48) 47 (57) 0.37 
ODI† mean (SD) 11.2 (15.7) - - 
ODI  0 – 5 (%) 13 (45) - - 
ODI > 5 (%) 16 (55) - - 
Baseline SaO2 Saturation % (SD) 97.3 (±0.47) - - 
Mean Sa02‡ %  (SD) 94.4 (± 0.79) - - 
SaO2 <90% in minutes (SD) 24.2 (±20.5) - - 
*AHI (Apnoea/Hypopnoea Index) = number of apnoea events per hour of sleep, > 5 classed as 
clinically significant; †ODI (Oxygen Desaturation Index) = number of time per hour oxygen saturation 
levels drop >3% from baseline; ‡SaO2 = peripheral capillary oxygen saturation levels 
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Table 5: Current MacTel Type 2 Disease Severity and retrospective two year progression analysis. 
 
 
 
 AHI ≤ 5 (n= 30) AHI > 5 (n = 28) p-value ODI ≤ 5 (n = 26) ODI > 5 (n = 32) p-value 
 
Mean GB Stage* (SD) 3.0 (1.0) 3.4 (0.96) 0.05 2.8 (1.0) 3.4 (1.0) 0.03 
Mean Increase in GB Stage over 2 years 0.38 (0.75) 0.11 (0.31) 0.09 0.31 (0.63) 0.18 (0.59) 0.41 
Mean BCVA† ETDRS letters (SD) 75 (14.1) 71 (17.6) 0.46 74 (15.2) 72 (16.6) 0.61 
Mean Change in LogMAR BCVA (SD) over 2 years -1.8 (4.1) -3.6 (7.6) 0.26 -2.1 (4.2) -3.0 (7.2) 0.58 
Mean CMT‡ (um)  236 (40.9) 218 (40.0) 0.08 233 (42.4) 222 (40.1) 0.35 
Mean Change in CMT (SD) over 2 years - 2.1 (25.0) -7.5 (27.0) 0.43 -0.2 (27.4) -8.9 (24.1) 0.2 
*GB Stage = Glass and Blodi disease staging for severity and progression of MacTel Type 2;      
†LogMAR BCVA = Logarithm of Minimum Angle of Resolution, Best Corrected Visual Acuity measured via ETDRS vision charts  
‡CMT = Central Macular Thickness as measured by spectral domain OCT (Optical Coherence Tomography). The change in BCVA and CMT was retrospectively 
evaluated over a 2 year period. 
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Seventy individuals enrolled in the MacTel Type 2 observational study were identified 
as eligible for the study and were contacted to participate in the first phase (Table 2). 
There were 13 non-responders, leaving 57 (81%) participants who completed the 
questionnaire. Based on sex, age, BMI, hypertension and diabetes, the Busselton 
Population and Medical Research Institute provided 165 case matched controls. 19 (33%) 
of the MacTel Type 2 participants and 55 (33%) of the controls were male. The mean age 
of the MacTel Type 2 subjects was similar to the control group. The mean body mass 
indices of the MacTel Type 2 and the control groups were also similar.   
 
The self reported outcomes of the BQ were similar between the 2 groups, with 23 (40%) 
of the MacTel Type 2 cohort and 49 (30%) of the control cohort having a positive finding 
of sleep disordered breathing (p = 0.95). The MacTel Type 2 cohort reported an Epworth 
Sleepiness Score of 6.4 (SD 5.0) whilst these values were unavailable for the control group.  
 
Using the ResMed ApneaLink™ device 30 MacTel Type 2 participants underwent 
overnight sleep analysis. The collaborators from the Busselton Health Study were able to 
identify 3 case-matches for each of 27 of MacTel Type 2 subjects. 2 subjects were matched 
on a 1:1 basis and one patient was excluded from the analysis as the subject was unable 
to be case matched on the basis of BMI (40.3 kg/m2). All case-control subjects completed 
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the BQ along with overnight sleep analysis using the single channel ResMed 
ApneaLink™. No oxymetry values were available for the case controls.  
 
The MacTel Type 2 cohort recorded a mean AHI of 9.55 episodes per hour (SD 14.65) 
which was similar to the control group (9.73 [SD 10.75] p = 0.95) (Table 3).  There was no 
significant difference in the distribution of MacTel Type 2 and control subjects within 
different severities of AHI outcomes: AHI 0 - 5, p = 0.57; AHI 6 – 15, p = 0.31; AHI 16 – 30, 
p = 0.13 and AHI > 30, p = 0.38.  
 
Using Gass and Blodi’s 1993 classification for the stage and progression of MacTel Type 
2 we were able to undertake analysis of the disease severity for those MacTel Type 2 
participants with and without OSA. The disease classification has 5 distinct stages 
which are arranged based on specific traits of the disease and the order in which they 
present. In early manifestations of the disease which mark stage 1 there is late 
perifoveal staining on fluorescein angiography. The disease classification then 
progresses with the loss of parafoveal transparency marking stage 2, the presence of 
blunted or right angled venules in stage 3 through to intraretinal pigment clumping in 
stage 4. Stage 5 marks the most severe stage of the disease and is classified based on the 
presence of subretinal neovascularisation. Using this MacTel Type 2 disease stage 
grading we were able to analyse the clinically significant parameters of OSA (AHI >5 
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and ODI >5) against this disease classification and found evidence to suggest that OSA 
was associated with a more advanced stage of MacTel Type 2. For those participants 
with a mean AHI ≤ 5 the mean GB stage was 3.0. When compared to a mean AHI > 5 the 
mean GB stage was significantly higher at 3.4 (p = 0.05). A similar finding was also 
present when comparing the ODI ranges. Those with a mean ODI of ≤ 5 had a mean GB 
stage of 2.8 and when compared to those with a mean ODI > 5 their mean GB stage was 
also significantly higher at 3.4 (p = 0.03)).  
 
The 2-year retrospective analysis with respect to key parameters  of MacTel Type 2 
disease progression (changes in visual acuity, CMT and stage of disease) found no 
significance between eyes with AHIs and ODIs ≤5 or >5. When comparing the BCVA 
letters there was no significant difference between those with and AHI ≤5 (-1.8 ETDRS 
letters) or >5 episodes per hour (-3.6 ETDRS letters) p = 0.26. It was a similar finding for 
the change in central macular thickness (CMT) with those with an AHI ≤ 5 reporting a 
reduction of 2.1µm over the 2 year analysis period compared to a reduction of 7.5µm over 
the same time frame for those with an AHI > 5 (p = 0.43). Finally the 2 year Gass and Blodi 
disease progression rates were also unremarkable with the AHI ≤ 5 reporting a mean 
change in disease progression of 0.38 stages compared to a change of 0.11 for the AHI > 
5 cohort (p = 0.09).  
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A similar analysis was also conducted to compare the change in ODI. The change in 
BCVA over the retrospective 2 year analysis period showed a similar change between the 
ODI ≤ 5 and those with clinically significant ODI > 5 (reduction of 2.1 vs 3 ETDRS letters 
respectively (p = 0.58)). There was also similarity with the change in CMT with the cohort 
with an ODI ≤ 5 reporting a mean reduction of 0.2µm vs a reduction of 8.9µm for the 
cohort with an ODI > 5 (p = 0.35). There was no significant difference in the change in 
Glass and Blodi disease stage over the 2 year retrospective observational period with the 
ODI ≤ 5 cohort experiencing a mean change in disease state of 0.31 vs 0.18 for the ODI > 
5 cohort (p = 0.41). 
 
The MacTel Type 2 cohort also underwent assessment of oxygen saturation levels as part 
of their ApneaLink™ assessment. The mean of baseline saturation levels was 97.3% (± 
0.47) whilst the mean saturation levels through the analysis period dropped to 94.4% (± 
0.79) with participants, on average, experiencing 24.2 minutes (SD ± 20.5) throughout the 
analysis period with saturation levels below 90%. Despite these values being unavailable 
for the control population a review of the literature shows the baseline saturation levels 
found in this study are representative for the normal population. Block et al. reported the 
baseline oxygen saturations levels of 49 asymptomatic men and women and found the 
mean saturation was 95% and 96% respectively with the mean change in saturation levels 
falling by 11% throughout the analysis period137.   
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2.4  Discussion 
 
The study was performed to determine whether OSA was more prevalent in patients with 
MacTel Type 2 and whether it was associated with more advanced macular disease that 
progressed more quickly than in patients without OSA. We found that there was a high 
prevalence of sleep disordered breathing in the cohort of patients with MacTel Type 2 
that we studied, however this was similar to appropriately matched case controls. We 
also found that patients with positive signs of OSA (AHI and ODI >5) had a significantly 
more advanced stage of MacTel Type 2 than those without signs of OSA. We found no 
significant difference between those with and without OSA in the parameters of MacTel 
Type 2 disease progression (change in visual acuity, central retinal thickness and Gass-
Blodi disease stage).  
 
Although this is the first study to assess the prevalence of sleep disordered breathing in 
the MacTel Type 2 population, the concept of an increased prevalence of sleep disordered 
breathing has been reported in other retinal diseases including diabetic macular oedema, 
central serous chorioretinopathy and retinal vein occlusions99 101 102 138 139. Amongst a cohort 
of eighty diabetic macular oedema patients, Mason et al. reported evidence of OSA (AHI 
> 5) in 65% of participants. The mean AHIs of this study (9.0 ]95% CI 3.0 – 16.5]) was 
similar to that of 9.6 (SD 14.7) amongst the MacTel Type 2 cohort in the present study.  
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A number of publications have reported an increased prevalence of OSA in patients with 
Central Serous Chorioretinopathy (CSCR)101 138 139. In an examination of 56 patients with 
CSCR, Kloos et al. reported 14 patients (38.8%) had an ESS > 10, of which 8 were 
confirmed to have OSA.138 . Using overnight polysonography examination of 23 patients 
with CSCR Yavas et al. reported a positive diagnosis of OSA (AHI > 5) in 14 (60.9%) 
participants139. 
 
The baseline characteristics of the MacTel Type 2 cohort in the present study were very 
similar to those reported by Clemons et al. from the larger, multicentre MacTel Type 2 
Natural History Observational Study5. The close association of baseline characteristics 
was also seen across the case controls, suggesting that appropriate matched controls had 
been selected for the present study. The mean age of the entire MacTel Type 2 cohort of 
62.4 years is very similar to the mean age of 61 years of our cohort. There was also a close 
association in BMI of the present study’s cohort and that reported by Clemons et al., 
29.8kg/m2 (SD = 4.7) versus 30kg/m2 (SD = 6), respectively. 67% of the current study’s 
cohort were female, similar to the 64% female population reported by Clemons et al.  
 
While the prevalence of OSA in the MacTel Type 2 cohort (table 3) was higher than is 
generally reported for the normal population, it was no different from the control group 
that had been matched on age, sex, BMI, hypertension and diabetic status. This was not 
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entirely unexpected given that patients with OSA and MacTel Type 2 have similar 
comorbidities such as hypertension and a high BMI. We also found that, of those who 
underwent overnight sleep analysis (table 4), nearly half of the MacTel Type 2 cohort 
showed some degree of OSA (AHI ≥ 5 episodes per hour) which again seems elevated 
when compared to the 2-4% prevalence estimate reported by Young et al.83 but again we 
postulate this may due to the confounding comorbitities seen in both OSA and MacTel 
Type 2. 
 
We found that patients with clinically significant sleep disordered breathing (AHI > 5) 
were likely to have a more advanced stage of MacTel Type 2 when compared to those 
MacTel Type 2 participants with an AHI within normal limits ( AHI ≤ 5) (Table 5). An 
explanation for this phenomenon may lie within the Müller cell. As the primary glial cell 
within the retina, one of the roles of the Müller cell is to protect photoreceptors from 
oxidative stresses through the upregulation of various antioxidants134. In one 
histopathological report into MacTel Type 2 a striking feature was a derangement of these 
cells in the central macula27. Recently, Powner et al. confirmed these manifestations of 
Müller cell derangement in MacTel Type 2 through a second histopathologic analysis of 
a 61 year old female140. (Powner et al.) Therefore, in patients with both MacTel Type 2 and 
OSA the episodic airway obstruction and subsequent sequelae in reduction of oxygen 
saturation levels seen in OSA coupled with the already compromised photoreceptors of 
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MacTel Type 2 may result in a more rapid progression of this retinal disease compared 
with patients without OSA. Over this 2 year observational period we were able to assess 
clinical changes that were felt would reflect progression (change in visual acuity, change 
in CMT and change in disease state) however, we were unable to report any significant 
differences in the rate of change of these variables in patients with and without OSA.  
 
The matched case-controlled design is a strength of this study as it allowed for the 
significant cofounders of hypertension, diabetes and obesity to be controlled. Other 
ophthalmological studies into sleep disordered breathing and retinal disease and sleep 
apnoea have compared their cohorts with historical controls identified through the 
literature102. The uncommon nature of MacTel Type 2 within the population meant that 
the cohort we studied was relatively small and the asymptomatic nature of MacTel Type 
2 in the early stages of the disease means that the possibility of individuals within the 
control cohort having undiagnosed MacTel Type 2 cannot be excluded.  
 
Although we were able to match control based on diabetes status (yes/no) having specific 
information regarding duration of diabetes or specific HbA1c levels would have 
provided a more rigid data set to which a closer association could have been possible. 
Unfortunately, these data were not available for the control participants.  
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This is the first study of its kind to suggest an association between MacTel Type 2 and 
OSA. There is scope for future studies to incorporate randomised clinical trials to identify 
a larger number of patients to test the hypotheses identified by the present study. As the 
disease progression of MacTel Type 2 is relatively slow future studies that follow patients 
for longer, potentially to 5 or more years, may find evidence for a stronger effect of OSA 
on MacTel Type 2. This disease progression may be measured more sensitively in future 
with new technologies, such as adaptive optics which may enable quantification of the 
stresses induced in photoreceptors through the episodic hypoxic event seen in patients 
with OSA. There is also scope to incorporate interventional CPAP studies to evaluate 
how the effective managements of OSA in patients MacTel Type 2 may result in a 
reduction in the progression rate of the retinal disease.  
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2.5  Conclusions 
 
 
Much is still unknown about the pathophysiology and factors affecting the progression 
of MacTel Type 2. Although not definitive in its outcomes, this study shows that the 
increased hypoxia experienced by patients with OSA and MacTel Type 2 may be 
associated with a more advanced stage of the MacTel Type 2.  
 
Although there was no difference in the prevalence of sleep disordered breathing when 
compared with case-matched controls, those MacTel Type 2 participants with clinical 
symptoms of sleep disordered breathing (AHI and ODI > 5 episodes per hour) generally 
had a more advanced stage of the disease. As such the results of this study may stimulate 
further clinical research that may have implications for the management of patients with 
MacTel Type 2.  
 
A randomized clinical trial may be warranted to determine whether treatment of OSA 
improves long term visual outcomes in people with MacTel Type 2. The rarity of MacTel 
Type 2 means that adequate patient populations for future large scale clinical trials may 
be difficult. However, the ongoing Natural History and Observational Registry for 
MacTel Type 2 may provide a suitable basis for which to commence. Future research may 
focus on larger patient sample sizes, the benefit of OSA management in MacTel Type 2 
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outcomes and also the involvement of novel technologies such as adaptive optics to 
assess the implications of hypoxia on photoreceptors.  
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4.1  Appendix 1: The Berlin Questionnaire
 
CATEGORY 1 
 
1. Do you snore? 
 a. Yes 
 b. No 
 c. Don’t know 
 
If you snore: 
 
2. Your snoring is: 
 a. Slightly louder than breathing 
 b. As loud as talking 
 c. Louder than talking 
 d. Very loud – can be heard in 
adjacent rooms 
 
3. How often do you snore 
  a. Nearly every day 
  b. 3-4 times a week 
  c. 1-2 times a week 
  d. 1-2 times a month 
  e. Never or nearly never 
 
4. Has your snoring ever bothered other 
people? 
  a. Yes 
  b. No 
  c. Don’t Know 
 
5. Has anyone noticed that you quit 
breathing during your sleep? 
  a. Nearly every day 
  b. 3-4 times a week 
  c. 1-2 times a week 
  d. 1-2 times a month 
  e. Never or nearly never 
 
 
 
 
 
 
CATEGORY 2 
 
6. How often do you feel tired or fatigued  
after your sleep? 
  a. Nearly every day 
  b. 3-4 times a week 
  c. 1-2 times a week 
  d. 1-2 times a month 
  e. Never or nearly never 
 
7. During your waking time, do you feel  
tired, fatigued or not up to par? 
  a. Nearly every day 
  b. 3-4 times a week 
  c. 1-2 times a week 
  d. 1-2 times a month 
  e. Never or nearly never 
 
8. Have you ever nodded off or fallen 
asleep while driving a vehicle? 
  a. Yes 
  b. No 
 
If yes: 
 
9. How often does this occur? 
 
 a. Nearly every day 
 b. 3-4 times a week 
 c. 1-2 times a week 
 d. 1-2 times a month 
 e. Never or nearly never 
 
CATEGORY 3 
 
10. Do you have high blood pressure? 
  Yes 
  No 
  Don’t know 
 79 
 
4.2   Appendix 2: Epworth Sleepiness Scale 
 
 
 
 
1. Berlin Questionnaire. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just 
tired? This refers to your usual way of life in recent times. Even if you have not done some of 
these things recently try to work out how they would have affected you. Use the following scale 
to choose the most appropriate number for each situation: 
 0 = would never doze 
 1 = slight chance of dozing 
 2 = moderate chance of dozing 
 3 = high chance of dozing 
It is important that you answer each question as best you can. 
Situation 
 
Chance of Dozing (0-3) 
1.   Sitting and reading  
2.   Watching TV  
3.   Sitting, inactive in a public place (e.g., a theatre or a meeting).....  
4.   As a passenger in a car for an hour without a break  
5.   Lying down to rest in the afternoon when circumstances permit  
6.   Sitting and talking to someone  
7.   Sitting quietly after a lunch without alcohol  
8.   In a car, while stopped for a few minutes in the traffic  
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4.3   Appendix 3: The SAMTel Sleep Questionnaire 
Thank you for participating in the SAMTel Questionnaire survey.  
This study is designed to evaluate those patients with Macular Telangiectasia (Mac Tel) for the 
presence of sleep disordered breathing.  Sleep disordered breathing is a common problem noted 
in adults. The most common form of sleep disordered breathing is obstructive sleep apnea 
syndrome (or OSA).  Patients with this condition often have breathing interruptions during sleep. 
In the Sleep Apnoea MacTel (SAMTel) study we will test our suspicion that sleep apnoea makes 
MacTel more likely to get worse. The questions in this survey are intended to help screen for sleep 
disordered breathing. From this information, further studies may be designed which will 
evaluate the actual prevalence and detail of sleep disordered breathing in those with Mac Tel.   
This study is being performed by the Woolcock Institute of Medical Research and the Macular 
Research Group of the Save Sight Institute under the direction of the Head of the Sleep and 
Circadian Research Group, Professor Ron Grunstein, and Professor Mark Gillies.  Professor 
Grunstein is a sleep specialist with broad experience in the study of sleep disorders and other 
diseases, while Professor Gillies is a clinician scientist who specialises in diseases of the macula. 
Your answers to these questions are important. This information will help guide the further study 
of any important overlap between sleep disordered breathing and Mac Tel.  Ultimately if a 
significant overlap exists, understanding how the two disorders interact may be important for 
the long-term therapy of such patients.   
All of your answers are held in confidence. No patient-identifiable data will ever be released for 
any reason. Answers will be combined across numerous responses and will be reported in a 
statistical sense.  Your participation in this survey is entirely voluntary. Your choice to participate 
or not participate will have no impact on your ability to access care and will not in any way alter 
your relationship with any care-givers.   
The survey consists of a number of questions. Please take your time and carefully consider each 
question. Choose the best answer from the options available. Please only select one answer when 
multiple choices are available. Questions may seem similar, but may actually ask questions in 
slightly different ways. When you have completed the questionnaire, please put it in the 
addressed return envelope and post it to the Save Sight Institute for analysis. 
If you have any questions, feel free to contact the researchers conducting the survey at: 
George Dungan      Martin Lee 
Woolcock Institute of Medical Research  Save Sight Institute 
Box M77       South Block, Sydney Hospital 
MISSENDEN ROAD, NSW 2050 AUSTRALIA 8 Macquarie Street 
Phone +61 (02) 9114 0007    Sydney NSW 2001  
e-mail: gdungan@woolcock.org.au   (02) 9382 7309 
                                                                                             e-mail: martin.lee@sydney.edu.au  
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Please fill in each question to the best of your ability. Where asked to select a choice, please use a ‘tick’ () 
in the appropriate box. All results are kept confidential. Only summarized and de-identified data will be 
used for analysis. 
1. Your INITIALS: ___________  2. DATE you are completing the Questionnaire: 
____/____/_____ 
3. AGE: _____ years 4. HEIGHT: ______ cm  5. WEIGHT: _____ kg      6. GENDER:  MALE    
FEMALE  
7. Year you were diagnosed with Macular Telangiectasia __________ 8. Currently being treated?   
Yes    No 
Do you suffer from any of the following (check the correct response): 
9. Hypertension / High Blood Pressure   Yes      No     If yes, are you being treated?   Yes      No 
10. Diabetes       Yes      No     If yes, are you being treated?   Yes      No 
11. Heart Disease      Yes      No     If yes, are you being treated?   Yes      No 
12. Stroke       Yes      No     If yes, are you being treated?   Yes      No 
13. Kidney Disease      Yes      No     If yes, are you being treated?   Yes      No 
14. Restless Leg Syndrome / Periodic    Yes      No     If yes, are you being treated?   Yes      No 
       limb movements of sleep 
15. Parasomnias (sleep walking/talking)   Yes      No     If yes, are you being treated?   Yes      No 
16. Insomnia       Yes      No     If yes, are you being treated?   Yes      No 
17. Narcolepsy      Yes      No     If yes, are you being treated?   Yes      No 
18. Sleep Apnea      Yes      No     If yes, are you being treated?   Yes      No 
19. If yes for Sleep Apnea, what treatment were you prescribed?:  
  CPAP     VPAP/BiLevel     Oral (dental) Splint     Other  ________________     
None 
19a. Do you regularly use your treatment?    Yes      No 
20.  Depression      Yes      No     If yes, are you being treated?   Yes      No 
20a. If yes for depression treatment, what treatment are you using? ________________________  
21. Do you have difficulty falling asleep?   
  Yes      No 
22. Do you have difficulty getting back to sleep after waking?  
  Yes      No 
23. Do you have uncomfortable feelings in your legs (for example, do you feel like you have to move 
them to relieve the discomfort)?   
  Yes      No 
24. Do you have difficulty staying awake during the day?  
  Yes      No 
25. Do you regularly take Sleeping pills (e.g., Stillnox®, Temaze, temazepam, zolpidem, etc.)?  
  Yes      No    What medication do you use? ______________________ 
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The following three questions refer to your behaviour while sleeping, trying to sleep, or while feeling 
sleepy. During the last month have you had, or have been told about the following symptoms? Please select 
only one choice for each question with a Tick in the appropriate box ( ): 
 
 
How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just tired? This 
refers to your usual way of life in recent times. Even if you have not done some of these things recently try 
to work out how they would have affected you. Use the following scale to choose the most appropriate 
number for each situation: 
 0 = would never doze 
 1 = slight chance of dozing 
 2 = moderate chance of dozing 
 3 = high chance of dozing 
It is important that you answer each question as best you can. 
Situation 
 
Chance of Dozing (0-3) 
29.   Sitting and reading  
30.   Watching TV  
31.   Sitting, inactive in a public place (e.g., a theatre or a meeting).....  
32.   As a passenger in a car for an hour without a break  
33.   Lying down to rest in the afternoon when circumstances permit  
34.   Sitting and talking to someone  
35.   Sitting quietly after a lunch without alcohol  
36.   In a car, while stopped for a few minutes in the traffic  
 
Note, please add any other comments you wish to make on these or any other questions here : 
26. Snoring or gasping 
  a. Never 
  b. Rarely (<1 time per week) 
  c. 1-2 times per week 
  d. 3-4 times per week 
  e. 5-7 times per week 
  f. Don’t know 
27. Loud snoring 
  a. Never 
  b. Rarely (<1 time per week) 
  c. 1-2 times per week 
  d. 3-4 times per week 
  e. 5-7 times per week 
  f. Don’t know 
28. Breathing stops, choke or struggle for 
breath 
  a. Never 
  b. Rarely (<1 time per week) 
  c. 1-2 times per week 
  d. 3-4 times per week 
  e. 5-7 times per week 
  f. Don’t know 
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CATEGORY 1 
37. Do you snore? 
 a. Yes 
 b. No 
 c. Don’t know 
 
If you snore: 
 
38. Your snoring is: 
 a. Slightly louder than breathing 
 b. As loud as talking 
 c. Louder than talking 
 d. Very loud – can be heard in 
adjacent rooms 
 
39. How often do you snore 
  a. Nearly every day 
  b. 3-4 times a week 
  c. 1-2 times a week 
  d. 1-2 times a month 
  e. Never or nearly never 
 
40. Has your snoring ever bothered other 
people? 
  a. Yes 
  b. No 
  c. Don’t Know 
 
41. Has anyone noticed that you quit 
breathing during your sleep? 
  a. Nearly every day 
  b. 3-4 times a week 
  c. 1-2 times a week 
  d. 1-2 times a month 
  e. Never or nearly never 
 
 
 
 
 
CATEGORY 2 
 
42. How often do you feel tired or 
fatigued  
after your sleep? 
  a. Nearly every day 
  b. 3-4 times a week 
  c. 1-2 times a week 
  d. 1-2 times a month 
  e. Never or nearly never 
 
43. During your waking time, do you feel  
tired, fatigued or not up to par? 
  a. Nearly every day 
  b. 3-4 times a week 
  c. 1-2 times a week 
  d. 1-2 times a month 
  e. Never or nearly never 
 
44. Have you ever nodded off or fallen 
asleep while driving a vehicle? 
  a. Yes 
  b. No 
 
If yes: 
 
45. How often does this occur? 
 
 a. Nearly every day 
 b. 3-4 times a week 
 c. 1-2 times a week 
 d. 1-2 times a month 
 e. Never or nearly never 
 
CATEGORY 3 
 
46. Do you have high blood pressure? 
  Yes 
  No
 
Please answer each question to the best of your ability. Tick the box () in front of the best answer 
for each question: 
